Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib + Temozolomide in IDH-Mutated Grade 3 Astrocytomas
NCT07215910Phase 3Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2026
- Primary completion
- May 2033
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vorasidenib in Astrocytoma, IDH-mutant, sponsored by Cancer and Leukemia Group B. Started Jun 2026; status: recruiting.
02
Drugs
vorasidenib
03
Conditions
Astrocytoma, IDH-mutant
Beyond the preview
Go deeper on NCT07215910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215910.